Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$1.38.

  • Cartesian Therapeutics' EPS (Basic) fell 2212.39% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.42, marking a year-over-year increase of 9730.09%. This contributed to the annual value of -$4.48 for FY2024, which is 9099.4% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported EPS (Basic) of -$1.38 as of Q3 2025, which was down 2212.39% from $0.51 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EPS (Basic) ranged from a high of $0.58 in Q2 2024 and a low of -$41.56 during Q4 2023
  • Over the past 5 years, Cartesian Therapeutics' median EPS (Basic) value was -$0.22 (recorded in 2021), while the average stood at -$3.35.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 20454.55% in 2022, then crashed by 10219003.13% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' EPS (Basic) stood at $0.12 in 2021, then plummeted by 66.08% to $0.04 in 2022, then tumbled by 102190.03% to -$41.56 in 2023, then surged by 96.62% to -$1.41 in 2024, then increased by 1.79% to -$1.38 in 2025.
  • Its EPS (Basic) stands at -$1.38 for Q3 2025, versus $0.51 for Q2 2025 and -$0.68 for Q1 2025.